A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)

• Status: Completed
• Trial end date: 2008-10-01

Summary

The purpose of this study is to assess how patients with gastro-oesophageal reflux disease (heartburn) who are currently receiving treatment with a proton pump inhibitor but are still experiencing symptoms will benefit from a change in treatment.

• Phase: Phase 4

Details

• Lead Sponsor: AstraZeneca
• Treatments: Esomeprazole; Proton Pump Inhibitors